Nkarta, Inc. (NKTX)
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Nkarta, Inc.
NASDAQ:NKTXHealthcare · Biotechnology
-6.02%$1.56
AH$1.60+2.56%vs close
Mkt Cap$111.73M
Float49.98M
O/S71.62M
Vol
$ Vol
RVOL
Inst Own82.9%
SI6.8%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$104.08M
Total Assets$404.21M
Free Cash Flow-$89.91M
Debt & Equity
Debt 20%
Equity 80%
Total Debt$76.42M
Total Equity$312.32M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in NKTX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$404.21M
Liabilities$91.88M
Accounts Receivable$2M
Accounts Payable$2.09M
Inventory$0
PP&E (Net)$101.15M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $115K | $6.55M |
| YoY Growth | - | - | - | - | - | - | -98.2% | - |
| Cost of Revenue | $9.19M | $0 | $5.87M | $0 | $0 | $0 | $17K | $4.25M |
| Gross Profit | -$9.19M | $0 | -$5.87M | $0 | $0 | $0 | $98K | $2.3M |
| Gross Margin | - | - | - | - | - | - | 85.1% | 35.1% |
| Research and Development | $90.43M | $96.74M | $90.9M | $90.9M | $63.41M | $36.22M | $17.22M | $4.25M |
| Selling, General, and Administrative | $31.57M | $31.45M | $34.88M | $28.06M | $23.02M | $15.29M | $5.25M | $2.65M |
| Other | -$9.98M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $112.01M | $128.19M | $125.78M | $118.95M | $86.43M | $51.51M | $22.46M | $6.91M |
| Operating Income (EBIT) | -$121.21M | -$128.19M | -$131.65M | -$118.95M | -$86.43M | -$51.51M | -$22.35M | -$356K |
| Operating Margin | - | - | - | - | - | - | -19368.7% | -5.4% |
| Interest Expense | $0 | $0 | $0 | $5.59M | $0 | $0 | $473K | $0 |
| Interest Income | $15.49M | $19.32M | $14.11M | $5.59M | $370K | $313K | $304K | $82K |
| Other Income (Expense) | $17.12M | $19.4M | $14.15M | $5.12M | $354K | -$39.85M | $1.27M | $82K |
| Income Before Tax (EBT) | -$104.08M | -$108.79M | -$117.5M | -$113.84M | -$86.08M | -$91.36M | -$21.08M | -$275K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $1.81M | $0 |
| Net Income | -$104.08M | -$108.79M | -$117.5M | -$113.84M | -$86.08M | -$91.36M | -$21.08M | -$275K |
| Net Income Margin | - | - | - | - | - | - | -18265.7% | -4.2% |
| Supplementary Data | ||||||||
| EPS | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | -1.59 | -2.55 | -0.01 |
| Diluted EPS | -1.41 | -1.60 | -2.40 | -2.61 | -2.62 | -1.59 | -2.55 | -0.01 |
| Weighted Average OS | 73.99M | 67.87M | 49.01M | 43.63M | 32.86M | 31.80M | 8.98M | 50.27M |
| EBITDA | -$94.89M | -$99.64M | -$120.48M | -$105.61M | -$84.32M | -$50.72M | -$20.2M | -$91K |
| EBITDA Margin | - | - | - | - | - | - | -17508.4% | -1.4% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $39.63M | $27.87M | $31.04M | $37.49M | $60.82M | $96.69M | $20.61M | $7.87M |
| Short-Term Investments | $236.65M | $239.48M | $217.15M | $314.65M | $177.27M | $218.22M | $16.38M | $0 |
| Cash and Short-Term Investments | $276.28M | $267.35M | $248.19M | $352.14M | $238.09M | $314.91M | $36.99M | $7.87M |
| Accounts Receivable | $2M | $200K | $200K | $1.3M | $0 | $0 | $0 | $150K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $117K |
| Other Current Assets | $414K | $2.54M | $1.42M | $1.63M | $3.15M | $1.34M | $67K | $94K |
| Total Current Assets | $282.51M | $273.34M | $253.07M | $360.69M | $245.78M | $318.83M | $37.47M | $8.23M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $101.15M | $110.67M | $119.28M | $107.66M | $24.53M | $17.86M | $10.22M | $1.29M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $16.11M | $110.39M | $2.74M | $2.74M | $0 | $0 | $269K | $90K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $4.44M | $6.8M | $3.8M | $1.85M | $3.59M | $960K | $455K | $0 |
| Total Long-Term Assets | $121.7M | $227.87M | $125.81M | $112.25M | $28.12M | $18.82M | $10.95M | $1.38M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $404.21M | $501.2M | $378.88M | $472.94M | $273.9M | $337.65M | $48.41M | $9.61M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $2.09M | $638K | $3.67M | $1.76M | $1.11M | $1.18M | $1.88M | $367K |
| Short-Term Debt | $0 | $0 | $0 | $4.25M | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $8K |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $2.7M | $0 |
| Other Current Liabilities | $6.07M | $254K | $6.72M | $9.35M | $96K | $117K | -$857K | $408K |
| Total Current Liabilities | $22.27M | $18.92M | $23.33M | $22.05M | $12.94M | $8.83M | $8.21M | $2.08M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $87K | $87K | $0 | $0 | $18K | $82K | $59.9M | $12.92M |
| Total Long-Term Liabilities | $69.62M | $74.31M | $82.27M | $78.69M | $9.99M | $7.6M | $65.68M | $12.92M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $91.88M | $93.23M | $105.6M | $100.73M | $22.94M | $16.43M | $73.89M | $15M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $60K | $12.71M |
| Common Stock | $7K | $7K | $5K | $5K | $3K | $3K | $160 | $123 |
| Retained Earnings | -$648.31M | -$544.22M | -$435.43M | -$317.93M | -$204.1M | -$118.02M | -$26.66M | -$5.58M |
| Comprehensive Income & Other | $407K | $674K | $8K | -$679K | -$150K | $3K | -$2K | -$245K |
| Other Stockholders' Equity | $960.63M | $952.19M | $708.71M | $690.13M | $455.06M | $439.24M | $1.18M | $188K |
| Total Equity | $312.32M | $407.98M | $273.29M | $372.21M | $250.97M | $321.22M | -$25.48M | -$5.4M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $404.21M | $501.2M | $378.88M | $472.94M | $273.9M | $337.65M | $48.41M | $9.61M |
| Supplementary Data | ||||||||
| Total Debt | $76.42M | $80.27M | $88.34M | $82.93M | $12.46M | $8.92M | $7.3M | $12.71M |
| Net Debt | $36.79M | $52.4M | $57.3M | $45.44M | -$48.36M | -$87.77M | -$13.31M | $4.84M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$104.08M | -$108.79M | -$117.5M | -$113.84M | -$86.08M | -$91.36M | -$21.08M | -$275K |
| Depreciation & Amortization | $9.19M | $9.15M | $5.87M | $2.64M | $1.76M | $786K | $401K | $183K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $3.24M | $738K | $0 | $0 |
| Stock-Based Compensation | $8.56M | $16.73M | $17.2M | $16.86M | $14.46M | $6.75M | $947K | $183K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | -$463K | -$15K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $2.46M | -$4.47M | $4.22M | $2.76M | $2.79M | $2.82M | $2.64M | $690K |
| Other Working Capital | -$2.9M | -$7.69M | $6.7M | $30.98M | -$4.43M | -$3.65M | $265 | -$5.95M |
| Total Working Capital Change | -$435K | -$12.16M | $10.93M | $33.74M | -$1.64M | -$828K | $2.18M | -$5.28M |
| Other Non-Cash Items | -$1.93M | -$4.63M | -$2.65M | $3.61M | $337K | $40.41M | -$818K | $549K |
| Net Cash from Operating | -$88.7M | -$99.7M | -$86.16M | -$57M | -$67.93M | -$43.51M | -$18.37M | -$5.18M |
| Investing Activities | ||||||||
| Capital Expenditures | -$1.21M | -$4.41M | -$28.15M | -$47.11M | -$5.03M | -$7.51M | -$1.93M | -$758K |
| Acquisitions | $0 | $0 | $0 | $138K | -$38K | $203K | $0 | $0 |
| Purchases of Investments | -$238.56M | -$406.38M | -$260.23M | -$385.89M | -$227.28M | -$222.57M | -$16.37M | $0 |
| Sales of Investments | $340.09M | $281.23M | $367.39M | $248.31M | $264.84M | $20M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | -$138K | $38K | -$203K | $0 | $0 |
| Net Cash from Investing | $100.32M | -$129.56M | $79.02M | -$184.69M | $32.53M | -$210.08M | -$18.3M | -$758K |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | - | -$64.32M | -$49.53M | - |
| Common Stock Issuance | $141K | $225.07M | $691K | $217.17M | $1.2M | $265.1M | $0 | $87K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $1.01M | $0 | $1.84M | $0 | -$63.92M | -$43.5M | $87K |
| Net Cash from Financing | $141K | $226.08M | $691K | $219.01M | $1.2M | $329.82M | $49.58M | $87K |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $11.76M | -$3.17M | -$6.45M | -$22.68M | -$34.19M | $76.23M | $12.92M | -$5.85M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$88.7M | -$99.7M | -$86.16M | -$57M | -$67.93M | -$43.51M | -$18.37M | -$5.18M |
| Capital Expenditure | -$1.21M | -$4.41M | -$28.15M | -$47.11M | -$5.03M | -$7.51M | -$1.93M | -$758K |
| Free Cash Flow | -$89.91M | -$104.11M | -$114.31M | -$104.11M | -$72.95M | -$51.02M | -$20.3M | -$5.94M |
| Cash at Beginning | $30.62M | $33.78M | $40.24M | $62.91M | $97.11M | $20.88M | $7.96M | $13.81M |
| Cash at End | $42.38M | $30.62M | $33.78M | $40.24M | $62.91M | $97.11M | $20.88M | $7.96M |